OLIGOMERIX has a significant portfolio of patents and pending applications (collectively its intellectual property or IP). The company employs a number of tactics to protect its intellectual property, including (1) broadly defining and patenting all processes and methods, (2) patenting each molecular entity, (3) maintaining close control over all trade secrets and (4) executing trademarks, as appropriate.

To date, the Company has several pending or provisional applications supporting its core technology. In addition, it has seven issued patents that it acquired from Q-RNA, Inc. The company’s patent counsel is Kalow & Springut, LLP, with expertise in law, sciences including chemistry, biochemistry, pharmacology, genetics, and business development.

Important patents have issued, are pending, or are in preparation related to focused development efforts that include:

• Methods and compositions for the identification, isolation, characterization and optimization of tau oligomers, Full Application filed August ’09 - priority date August ’08 - claims specific tau oligomer forms based on their chemical composition and uses for drug screening, and as antigens for immunotherapeutic approaches
  
  
• Animal model for screening compounds and antibodies targeting tau oligomers– with Columbia University - CIP submitted March 8, 2010 - Priority date September ’07 – therapeutics are screened for restoration of associative memory inhibited by application of tau oligomers
  
  
• Synaptic plasticity model for screening compounds inhibiting tau oligomers – with Columbia University - Long term potentiation (LTP) assay for compound screening, Priority date September ’07 – claims ex vivo assay to determine the effect of compounds on tau protein induced reduction of LTP in a neural structure (model memory assay)
  
  
• Tau Protease Composition and Methods US full application submitted August 20 ’09 – priority date August ’08 – claims protease activity leads to irreversible loss of tau function and gain of toxic function by production of aggregation-prone fragments of tau
  
  
• Oligomerization of tau protein as a target for drug discovery
  
  
• High throughput screening system based on tau oligomers
  
  
• Tau oligomers as diagnostic indicators of disease progression (biomarker) - Biomarkers for AD and assays therefore - Priority date February ’07 – claims biomarker assays for drug discovery and diagnostic assay development based on targeting tau oligomers in CSF and plasma
  
  
• Compositions & methods for identifying factors for aggregation - Methods for screening compounds inhibiting tau oligomer formation and disrupting them. Priority date February ’06 claims methods for generating stable oligomers of amyloid proteins and assays for evaluating the effect of compounds

Back to Technology